157 related articles for article (PubMed ID: 36255176)
61. Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin.
Hahn MA; Marsh DJ
Oncogene; 2005 Sep; 24(41):6241-8. PubMed ID: 16116486
[TBL] [Abstract][Full Text] [Related]
62. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
Tan MH; Morrison C; Wang P; Yang X; Haven CJ; Zhang C; Zhao P; Tretiakova MS; Korpi-Hyovalti E; Burgess JR; Soo KC; Cheah WK; Cao B; Resau J; Morreau H; Teh BT
Clin Cancer Res; 2004 Oct; 10(19):6629-37. PubMed ID: 15475453
[TBL] [Abstract][Full Text] [Related]
63. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver.
Takahashi A; Tsutsumi R; Kikuchi I; Obuse C; Saito Y; Seidi A; Karisch R; Fernandez M; Cho T; Ohnishi N; Rozenblatt-Rosen O; Meyerson M; Neel BG; Hatakeyama M
Mol Cell; 2011 Jul; 43(1):45-56. PubMed ID: 21726809
[TBL] [Abstract][Full Text] [Related]
64. Novel nonsense CDC73 mutations in Chinese patients with parathyroid tumors.
Siu WK; Law CY; Lam CW; Mak CM; Wong GW; Ho AY; Ho KY; Loo KT; Chiu SC; Chow LT; Tong SF; Chan AY
Fam Cancer; 2011 Dec; 10(4):695-9. PubMed ID: 21732217
[TBL] [Abstract][Full Text] [Related]
65. Immunohistochemical assessment of parafibromin in mouse and human tissues.
Porzionato A; Macchi V; Barzon L; Masi G; Iacobone M; Parenti A; Palù G; De Caro R
J Anat; 2006 Dec; 209(6):817-27. PubMed ID: 17118068
[TBL] [Abstract][Full Text] [Related]
66. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
[TBL] [Abstract][Full Text] [Related]
67. The tumor suppressor parafibromin is required for posttranscriptional processing of histone mRNA.
Farber LJ; Kort EJ; Wang P; Chen J; Teh BT
Mol Carcinog; 2010 Mar; 49(3):215-23. PubMed ID: 19908240
[TBL] [Abstract][Full Text] [Related]
68. Parafibromin inhibits cancer cell growth and causes G1 phase arrest.
Zhang C; Kong D; Tan MH; Pappas DL; Wang PF; Chen J; Farber L; Zhang N; Koo HM; Weinreich M; Williams BO; Teh BT
Biochem Biophys Res Commun; 2006 Nov; 350(1):17-24. PubMed ID: 16989776
[TBL] [Abstract][Full Text] [Related]
69. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
Li Y; Yang W; Yang Q; Zhou S
Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
[TBL] [Abstract][Full Text] [Related]
70. The clinicopathological and prognostic significances of LATS1 expression in breast cancer.
Zheng HC; Xiang LW; Cui ZG; Xue H; E Y; Zhao MZ
Histol Histopathol; 2022 Jul; 37(7):665-677. PubMed ID: 35142365
[TBL] [Abstract][Full Text] [Related]
71. Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function.
Lin L; Czapiga M; Nini L; Zhang JH; Simonds WF
Mol Cancer Res; 2007 Feb; 5(2):183-93. PubMed ID: 17314275
[TBL] [Abstract][Full Text] [Related]
72. Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.
Cardoso L; Stevenson M; Thakker RV
Hum Mutat; 2017 Dec; 38(12):1621-1648. PubMed ID: 28881068
[TBL] [Abstract][Full Text] [Related]
73. Upregulation of FGFR1 expression is associated with parathyroid carcinogenesis in HPT-JT syndrome due to an HRPT2 splicing mutation.
Lee JY; Kim SY; Mo EY; Kim ES; Han JH; Maeng LS; Lee AH; Eun JW; Nam SW; Moon SD
Int J Oncol; 2014 Aug; 45(2):641-50. PubMed ID: 24889687
[TBL] [Abstract][Full Text] [Related]
74. The clinicopathological and prognostic significances of Dkk3 expression in cancers: A bioinformatics analysis.
Chen GY; Zheng HC
Cancer Biomark; 2018; 23(3):323-331. PubMed ID: 29843219
[TBL] [Abstract][Full Text] [Related]
75. The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination.
Hahn MA; Dickson KA; Jackson S; Clarkson A; Gill AJ; Marsh DJ
Hum Mol Genet; 2012 Feb; 21(3):559-68. PubMed ID: 22021426
[TBL] [Abstract][Full Text] [Related]
76. UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer.
Xiang G; Wang S; Chen L; Song M; Song X; Wang H; Zhou P; Ma X; Yu J
Cell Death Dis; 2022 May; 13(5):451. PubMed ID: 35551175
[TBL] [Abstract][Full Text] [Related]
77. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.
Sulaiman L; Haglund F; Hashemi J; Obara T; Nordenström J; Larsson C; Juhlin CC
PLoS One; 2012; 7(9):e46325. PubMed ID: 23029479
[TBL] [Abstract][Full Text] [Related]
78. [CDC73 mutations in young patients with primary hyperparathyroidism: A description of two clinical cases].
Mamedova EO; Mokrysheva NG; Pigarova EA; Przhiyalkovskaya EG; Voronkova IA; Vasilyev EV; Petrov VM; Gorbunova VA; Rozhinskaya LY; Belaya ZE; Tyulpakov AN
Ter Arkh; 2016; 88(10):57-62. PubMed ID: 27801421
[TBL] [Abstract][Full Text] [Related]
79. CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.
van der Tuin K; Tops CMJ; Adank MA; Cobben JM; Hamdy NAT; Jongmans MC; Menko FH; van Nesselrooij BPM; Netea-Maier RT; Oosterwijk JC; Valk GD; Wolffenbuttel BHR; Hes FJ; Morreau H
J Clin Endocrinol Metab; 2017 Dec; 102(12):4534-4540. PubMed ID: 29040582
[TBL] [Abstract][Full Text] [Related]
80. The Relation of Parafibromin Expression with Clinicopathological Factors in Invasive Breast Carcinomas.
Karaarslan S; Genç B; Nart A; Börekçi İ; Buğdayci MH
Turk Patoloji Derg; 2016; 32(1):8-14. PubMed ID: 26832176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
